
The Pharmaceutical Products Factory Project represents a strategic industrial investment aimed at supporting the national healthcare system and strengthening pharmaceutical security by producing a wide range of pharmaceutical formulations — including tablets, capsules, creams, ointments, syrups, drops, and sterile solutions — using the latest European production lines that ensure superior quality in accordance with international standards.
The factory targets the local market’s needs by offering various products such as pain relievers, joint treatment gels, cough medicines, and pharmaceutical supplements. Its customer base includes pharmacies, hospitals, medical complexes, and pharmaceutical distributors, ensuring wide market reach to end consumers.
The project also contributes to localizing the pharmaceutical manufacturing industry and reducing dependence on imports, thereby supporting national efforts toward achieving self-sufficiency in this vital sector. Thanks to its flexible and diverse production lines, the factory has a strong ability to adapt to changing market demands, opening promising opportunities for growth and expansion both locally and regionally
The global pharmaceutical market has witnessed remarkable growth in recent years, driven by the increasing demand for healthcare services and technological advancements in manufacturing and distribution. According to recent estimates, the market size reached USD 1,747.07 billion in 2024 and is expected to grow to USD 1,864.73 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.7%. This ongoing expansion highlights the vitality of the global pharmaceutical sector. Projections indicate that this upward trend will continue, with the market expected to reach approximately USD 2,384.53 billion by 2029, at a CAGR of 6.3% between 2025 and 2029.
This growth momentum is driven by key factors, including rising health awareness, the expansion of healthcare insurance programs across many countries, and continuous innovation in developing new and effective medicines. These indicators clearly demonstrate the attractiveness of the pharmaceutical industry to investors and confirm the sustainability of promising opportunities in this sector over the medium and long term.
Establishing a pharmaceutical products factory in Qatar represents a strategic investment opportunity aligned with the nation’s efforts to achieve self-sufficiency and strengthen healthcare security. The operating revenues in the pharmaceutical sector are projected to reach QAR 1.7 billion in 2025, with expectations to grow to QAR 2.6 billion by 2033, reflecting the increasing domestic demand for pharmaceutical products.
This initiative supports Qatar National Vision 2030, which aims to develop a robust local pharmaceutical industry as a cornerstone of the knowledge-based economy and reduce reliance on imports. The Qatari market is characterized by limited local competition, with a high dependence on imported drugs and only a few operational pharmaceutical factories.
Furthermore, the Qatari government strongly supports national industrial initiatives by prioritizing local products in public and private procurement. The factory will adopt advanced pharmaceutical manufacturing systems compliant with international standards such as FDA, GMP, and ISO, alongside an integrated smart quality control system covering all stages from material receipt to distribution. This ensures the highest levels of quality, regulatory compliance, and operational efficiency, enhancing the project’s potential for long-term success and sustainability.
Get a Feasibility Study